These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 24236820)

  • 21. Targeted therapy for melanoma: rational combinatorial approaches.
    Kwong LN; Davies MA
    Oncogene; 2014 Jan; 33(1):1-9. PubMed ID: 23416974
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Syntheses, biological evaluation and SAR of ingenol mebutate analogues for treatment of actinic keratosis and non-melanoma skin cancer.
    Liang X; Grue-Sørensen G; Månsson K; Vedsø P; Soor A; Stahlhut M; Bertelsen M; Engell KM; Högberg T
    Bioorg Med Chem Lett; 2013 Oct; 23(20):5624-9. PubMed ID: 23993332
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New therapeutical strategies in the treatment of metastatic disease.
    Julia F; Thomas L; Dalle S
    Dermatol Ther; 2012; 25(5):452-7. PubMed ID: 23046024
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alternatives for the treatment of local advanced disease: electrochemotherapy, limb perfusion, limb infusion, intralesional IL2. What is the role?
    Testori A; Intelisano A; Verrecchia F; Menicanti C; Tosti G; Grassi E; Pari C; Pennacchioli E
    Dermatol Ther; 2012; 25(5):443-51. PubMed ID: 23046023
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination chemoprevention with diclofenac, calcipotriol and difluoromethylornithine inhibits development of non-melanoma skin cancer in mice.
    Pommergaard HC; Burcharth J; Rosenberg J; Raskov H
    Anticancer Res; 2013 Aug; 33(8):3033-9. PubMed ID: 23898057
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospects for non-immunological molecular therapeutics in melanoma.
    Eustace AJ; Mahgoub T; Tryfonopoulos D; O'Donovan N; Crown J
    J BUON; 2010; 15(1):9-18. PubMed ID: 20414921
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adjuvant therapy for malignant melanoma.
    Stoutenburg JP; Schrope B; Kaufman HL
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):823-35. PubMed ID: 15485316
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Demodex as a Delivery Vector for Topical Targeted Medications in the Skin for Early Melanoma and Non-Melanoma Skin Cancer.
    Strobel SL
    Ann Clin Lab Sci; 2017 Sep; 47(5):604-605. PubMed ID: 29066489
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiangiogenic and antiapoptotic treatment in advanced melanoma.
    Nikolaou V; Stratigos A; Bafaloukos D; Katsambas A
    Clin Dermatol; 2013; 31(3):257-63. PubMed ID: 23608445
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel treatment strategies for malignant melanoma: a new beginning?
    Kasper B; D'Hondt V; Vereecken P; Awada A
    Crit Rev Oncol Hematol; 2007 Apr; 62(1):16-22. PubMed ID: 17208006
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Melanoma: from darkness to promise.
    Gasent Blesa JM; Grande Pulido E; Alberola Candel V; Provencio Pulla M
    Am J Clin Oncol; 2011 Apr; 34(2):179-87. PubMed ID: 20498590
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ingenol mebutate: an introduction.
    Fallen RS; Gooderham M
    Skin Therapy Lett; 2012 Feb; 17(2):1-3. PubMed ID: 22358305
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomized phase IIa trial.
    Siller G; Rosen R; Freeman M; Welburn P; Katsamas J; Ogbourne SM
    Australas J Dermatol; 2010 May; 51(2):99-105. PubMed ID: 20546215
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is there a role for targeting vascular endothelial growth factor/receptor axis in the treatment of patients with metastatic melanoma?
    Kim KB
    Cancer; 2013 Feb; 119(3):477-80. PubMed ID: 22915026
    [No Abstract]   [Full Text] [Related]  

  • 35. Trends in the treatment and detection of skin cancer.
    Emer J; Markowitz O
    J Drugs Dermatol; 2011 Jan; 10(1):16-8. PubMed ID: 21197515
    [No Abstract]   [Full Text] [Related]  

  • 36. Natural Compounds in Non-Melanoma Skin Cancer: Prevention and Treatment.
    Kowalski S; Karska J; Tota M; Skinderowicz K; Kulbacka J; Drąg-Zalesińska M
    Molecules; 2024 Feb; 29(3):. PubMed ID: 38338469
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improving topical non-melanoma skin cancer treatment: In vitro efficacy of a novel guanosine-analog phosphonate.
    Ali-von Laue C; Zoschke C; Do N; Lehnen D; Küchler S; Mehnert W; Blaschke T; Kramer KD; Plendl J; Weindl G; Korting HC; Hoeller Obrigkeit D; Merk HF; Schäfer-Korting M
    Skin Pharmacol Physiol; 2014; 27(4):173. PubMed ID: 24503861
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemotherapy: uses and safety considerations.
    Alexander J
    Dermatol Nurs; 1991 Apr; 3(2):107-9. PubMed ID: 1826843
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current status of pharmacogenomics testing for anti-tumor drug therapies: approaches to non-melanoma skin cancer.
    Grealy R; Griffiths LR
    Mol Diagn Ther; 2009; 13(2):65-72. PubMed ID: 19537842
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Innovative Topical Patches for Non-Melanoma Skin Cancer: Current Challenges and Key Formulation Considerations.
    Kim S; Day CM; Song Y; Holmes A; Garg S
    Pharmaceutics; 2023 Nov; 15(11):. PubMed ID: 38004557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.